In a phase III trial, a chemotherapy regimen of fluorouracil, oxaliplatin, and docetaxel (TFOX) improved survival outcomes over standard FOLFOX for patients with advanced HER2-negative gastric cancer.

To determine the optimal chemotherapy backbone for testing in future US cooperative group studies for metastatic esophageal and gastroesophageal junction cancers. Cetuximab was added to each treatment ...

Merck, a leading science and technology company, will present data at the ESMO 18 th World Congress on Gastrointestinal Cancer (WCGC) from the pivotal Phase III TAILOR study in patients from China, ...

Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...